Daily Stock Setups

StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc.

Posted on: Wed, 18 Nov 2009 06:51:00 EST

Symbols: KG, JNJ, WPI, ARNA

Are you looking to increase your ETF knowledge?

DALLAS, Nov 18, 2009 (GlobeNewswire via COMTEX) --
WPI | Quote | Chart | News | PowerRating -- StockPreacher.com announces an investment report featuring biopharmaceutical company Arena Pharmaceuticals Inc. (Nasdaq: ARNA | Quote | Chart | News | PowerRating). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/ARNA

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

Arena Pharmaceuticals Inc. (ARNA) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. The Company's drug candidate, lorcaserin hydrochloride (lorcaserin), is being investigated in a phase III clinical trial program for the treatment of obesity.

Message Board Search for ARNA: http://www.boardcentral.com/boards/ARNA

In the report, the analyst notes:

"Arena reported a lower net loss allocable to common stockholders in the third quarter of 2009 of $34.8 million, or $0.38 per share, compared to a net loss allocable to common stockholders in the third quarter of 2008 of $56.2 million, or $0.76 per share, and a net loss allocable to common stockholders in the first nine months of 2009 of $123.4 million, or $1.51 per share, compared to a net loss allocable to common stockholders in the first nine months of 2008 of $177.0 million, or $2.40 per share.

"In late October, ARNA reported data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) phase III trial that demonstrated improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings added to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients. The late-breaking data were presented by Lee Kaplan, M.D., Ph.D., associate professor of Medicine at Harvard Medical School and director of the Massachusetts General Hospital Weight Center, at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society."

To read the entire report visit: http://www.stockpreacher.com/n/ARNA

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: StockPreacher

CONTACT:  StockPreacher.com
Jeff Bishop
(469)-252-3505
press@beaconequity.com

For full details on King Pharmaceuticals Inc (KG) KG. King Pharmaceuticals Inc (KG) has Short Term PowerRatings at TradingMarkets. Details on King Pharmaceuticals Inc (KG) Short Term PowerRatings is available at This Link.

For full details on Johnson & Johnson (JNJ) JNJ. Johnson & Johnson (JNJ) has Short Term PowerRatings at TradingMarkets. Details on Johnson & Johnson (JNJ) Short Term PowerRatings is available at This Link.

For full details on Watson Pharmaceuticals (WPI) WPI. Watson Pharmaceuticals (WPI) has Short Term PowerRatings at TradingMarkets. Details on Watson Pharmaceuticals (WPI) Short Term PowerRatings is available at This Link.

For full details on Arena Pharmaceuticals (ARNA) ARNA. Arena Pharmaceuticals (ARNA) has Short Term PowerRatings at TradingMarkets. Details on Arena Pharmaceuticals (ARNA) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.